BVNRY BAVARIAN NORDIC
$11.68
BAVARIAN NORDIC Q3 F2026 Earnings Call Transcript
AI Conference Call Analysis
Sign in or subscribe to read.Conference Operator
Operator
Good day and thank you for standing by. Welcome to the Bavarian Nordic third quarterly report for the nine-month period ended 30 September 2026. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 and one again. Please be advised that this conference is being recorded. I would now like to hand the conference over to your speaker today, Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead.
Anders Hjort
Head of Investor Relations
Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Hjort, Head of Investor Relations. Please go ahead. Anders Then turning to slide number three, just shortly in terms of the agenda for today that we will cover. First of all, we'll go through the key highlights, starting to travel health and public preparedness, the pipeline and our commercial performance. And we'll finish up with the financial and the outlook for 2026. And then of course, also the Q&A. So I'll now hand over the mic to the CEO, Tara Stenbaum.
Tara Stenbaum
Chief Executive Officer
Thank you Anders. Good morning and good afternoon everyone and a warm welcome also from my side. This is my first earnings call for Bavaria Nordic and I'm very pleased that we can report another quarter of strong performance, providing a really solid foundation for Bavaria Nordic's next chapter. Before going into the numbers, let me share shortly some of my first thoughts as a new CEO. First of all, I am very excited to have joined Bavarian Nordic and I look forward to leading the company into the next stage of growth. I'm also looking forward to getting to know all of you on this course and through our wider investor engagement. Many of you may already be familiar with my background and that's what you can expect from me. Having served close to 30 years in large global pharmaceutical companies, including leading a vaccines business My focus has been on growing and transforming businesses, building long-term partnerships with government, health authorities, and then importantly, making clear choices about where to invest and grow. I've now been with the Bavarian Nordic for about a month, and naturally, I am still in the listening and learning phase. I spend much of the time with our teams and our sites, with our authors, key stakeholders, but this has left me already with Some observations. Firstly, I see speed and agility driven by purpose. People here solve problems without waiting for directions. They have a sense of urgency driven by a shared purpose of making life-saving vaccines available to more people. Secondly, I see a delivery under pressure with a real learning culture. Challenges surface early and there's a strong appetite to keep improving. They are really hungry to learn. And then finally, but very importantly, I see as well deep expertise and trusted relationships. We have deep knowledge of infectious diseases and a strong network with government and public authorities we work with. These trusts have obviously been built over many years and I do see it as a real asset to build on. So Bavarian Nordic has a good foundation and an encouraging momentum to build on. Together with our leadership team and the board, we've started to identify the key questions we need to explore in depth over the coming months to sharpen our strategy, such as how do we fully capture the world's potential in travel health, especially in rapeseed and the vinconia loans, and strengthen our position in the key markets, such as the U.S.? How do we deepen our partnerships with governments to create a long-term predictability in public health? And then with demand, How do we build a manufacturing and supply network that supports our growth efficiently and competitively? And then how do we build on our vaccine expertise and platform to scale the business both organically and through business development and acquisitions? The objective is simple, to make clear choices about where we focus our efforts and investments to create long-term value. We will share our strategic priorities in the first half of 2027, including our approach to capital allocation. In the meantime, we will remain fully focused on keeping our momentum and delivering on our commitments. Then, turning to the Q3 results. For the first nine months, revenue was just under 4.9 billion BKK, representing reported growth of 2%. For the discontinued partnerships and foreign exchange, organic growth was over 9%. The region margin was exceptionally strong, close to 35%, also reflecting the facing R&D and commercial investments in the Q4. Travel health grew 22% in the third quarter and 24% in the first nine months. If we exclude discontinued partnerships, growth was over 30%. The main driver is continued momentum in gravies, especially in the U.S., but across geographies, supported by the ongoing launch of Emplinia and the rest of the portfolio. Public preparedness is in line with our expectations and remains above our annual base level. We secured around $2.4 billion for 2026 and secured around $900 million for 2027. That includes our new four-year contract with the UK government, a really good example of the long-term partnerships we want to build. Our financial position is strong. We completed the first half of our share buyback in October, and we're starting a second half of up to 250 million DKK today. We're maintaining our 2026 outlook, revenue of around 6.1 billion, including approximately 4 billion from travel help, and Editha Martin, all around 32%. In summary, Q2 was another quarter of strong performance, reflecting the strength of our business, solid execution, and our continued ability to deliver on our commitments. I want to recognize the dedication and efforts of our team, the Gross Bavarian Nordic, whose contributions have been instrumental in delivering these results. With this overview, I will hand over to Henrik, our CFO, who will take you through the performance and the business in more detail. As you have heard, or actually read in the announcement this morning, Henrik has taken a decision to step down as our CFO this coming spring. We've initiated a search, and I'm confident we can do a smooth transition. Although Henrik is not going anytime soon, I already want to recognize his big contribution for Bavarian Nordic and also on my onboarding that is of course still ongoing.
Henrik Juuel
Chief Financial Officer
Henrik, please. Thank you very much, Taja. Good to have you here at your first earnings call, really. Let's not spend too much time on my situation. This is about the quarter, but I can only say there's absolutely no drama involved in my desire to step down as the CFO. Absolutely not. It's done in a good way. Good manner and I'm sure we will secure some good handover and transition to my successor and to Thaya as well. So let's focus on the quarter this time here. As Thaya said, very strong numbers we have just reported this morning here and I will spend a little time on the next slide here looking at first our travel health business and then public preparedness after that. So let's start with travel health that demonstrated extremely high growth numbers, 32% for the quarter and 34% for the nine months if we adjust for the discontinued partner business we used to have with Reneva and Dynavax. So very, very strong growth. To a large extent, driven by continued strong momentum within our rapist business, but also supported by the continued launch of vincunia, our chikungunya vaccine, and actually also by TBE when we look at TBE on a nine-month basis. If we dive into the rapist business, then we have seen continued very, very strong market growth across markets, but in particularly outspoken in the US market, which we have seen growing by 36% first nine months compared to prior year. And here you need to understand that it has actually been an accelerating growth. In the beginning of the year, we saw closer to the 20% growth. Thank you very much. Thank you. The US explained a lot of it, as I said, but we also see significant growth in the several European markets and we start to see the markets we took back from Geneva actually also contributing to the growth of our radius business. If we then turn to tick-borne encephalitis or Ensecor vaccine, then we have to acknowledge that this year has been a challenging year for our TBE business. We entered the year with Rolf Sass Sørensen But we are very, very happy that when we look at this business on a year-to-date basis, we have actually delivered a 9% growth. And due to a tremendous effort by our commercial organization, we have maintained our markets here. But it's obvious that when we look at the quarter by quarter, we have seen positive quarters. And now in the third quarter here, we actually saw negative growth due to some of the challenges we're facing. But over the year, 9% growth. I think we can be very happy with that given the situation we were in. We are right now leaving the TBE season and our issues should hopefully be resolved or they are resolved right now so we are ready to enter into the next season starting in spring next year. Let's spend a little more time on rapists as it explains so much of our growth at the moment. So if we turn to the next slide. To talk a little about the underlying growth drivers for the continuous strong growth of the rapist markets. And here let's focus on the U.S., which is the key contributor to the growth. I think what we're seeing right now in the U.S. is that rapists is endemic in the U.S. and the areas where you see increased rapist activities are just expanding. That is evidenced by some of the monitoring that the U.S. CDC is doing. Several hot spots have been identified in the U.S. In different states with elevated rapist activity. And it has also been seen that the rapist is spreading to more animal species. It used to be mainly bats, but now it's also other types of animals as well. And that combined with people spending a lot of time outdoor, it's a lot of many more situations that we usually have with human to animal encounters, and that drives What we call the exposure vaccinations. So when people are in contact with rapid animals in the nature, you have to immediately go to the emergency clinic and get vaccinated. And as this is a deadly disease, there's a lot of media attention around these statistics. And that again, that media attention creates a demand for vaccinations ahead of any risks. So that is the pre-exposure segment of the market that is therefore also seeing a quite significant increase. So very, very strong demand driven by the endemic situation in the US at the moment. We get a lot of questions around is this a sustainable situation we see or what's going to happen going forward. I think first of all, I think we have to be honest and say it's a difficult market to forecast in as not only is the market increasing, it's the growth in itself has been accelerating. So we are, of course, looking into how we can forecast this better going forward. But as we sit here right now, we see no signs that the market should decline again. We are dealing with animals that are infected by rages in the nature, so it's much more difficult to control than an outbreak in human people that you can actually vaccinate. So, so far, no signs that the market should suddenly decline again. Let's turn to the next slide, which talks about one of our other growth drivers. That is our chicken gunja vaccine, Vimkunja, which we have now launched in most of Europe and in the U.S. as well. I think we have on a nine-month basis, we have now delivered 151 million Danish kroner. And as you will recall, we are targeting 200 million for the full year. We have seen so far very good performance in several European markets. Germany in particular has actually exceeded our expectations. I think where we are still challenged is in the U.S. market, where we, to be honest, we are not living up to our own expectations yet. But what we have seen is the U.S. taking a rather conservative approach to the recommendation, and at the same time the recommendation from ACIP has not yet been confirmed in the MMWR publication. So it does give us some short-term headwinds still in the US to be resolved. We are though quite confident that the US will eventually become one of our key markets also for this product here. This is a disease, Chikungunya, that is just in its infancy, if you ask us. We have seen, even last week, we saw local transmission of this disease in Switzerland. So the mosquito that is spreading this type of disease is spreading to many more territories. and therefore we do believe that there is a very significant future potential in this area. So turning to the next slide and let's talk about the other business leg. We have our public preparedness business. We have in the third quarter, we have delivered on the orders that we have secured already. So performance in line with our expectations approximately 1.9 billion Danish kroner. We are targeting 2.5 billion for the full year, and we have already secured 2.4 of those by contract. So we need still to close a small gap in terms of contracting, but we are very confident that that is going to happen as well. Remember, when we entered the year, we regarded this year to be a more normalized year with no inbox impact as we saw in the three to four previous years. and therefore we lowered our expectations to this year. But despite that, we have managed to get some good, large contracts enabling us to deliver 2.5 billion this year, which is about our normal business base level of 1.5 to 2 billion. So again, strong execution on public preparedness. We're very happy that we earlier this year managed to, in Europe, to extend the label. to include children aged 2 to 12. And we have some more ongoing trials that will eventually help us to further expand the label for this vaccine. On the next two slides, I just wanted to share a couple of recent developments within our public preparedness business. And I think on the first one here, we talk about the initiative taken by the International Coordination Group on Vaccine Provision. Thank you very much. Thank you very much. ICT, the International Coordination Group, can allocate these according to the needs. So a very, very good development, securing vaccine access to low- and middle-income countries. On the next slide, another good development. We have recently announced that we were awarded a contract with the UK government. The very interesting thing with this contract is that it's a multiyear contract. It's a four-year contract to supply mpox, smallpox vaccines to the UK government. We do not have many of those, and it has been the cause of some of the volatility we have seen in our public preparedness business in the past has been that governments typically wouldn't commit beyond one year. So this is a very good sign of our long-standing partnership with the UK government. Enough about the commercial business, then a very quick update on our pipeline, which you will see on the page now. Overall, all our programs, they are on track. We are running post-approval committed studies on chikungunya. We are developing the cell line manufacturing process for our MVA, smallpox, mpox vaccine, which is now running in phase two. and we are also in phase two with an equine encephalitis vaccine development, fully funded by the US government. And then we do have two preclinical assets, Lyme assets, where we anticipate to go into the clinic in 28, and then our EBV preclinical assets, which we still believe should enter the clinic this year. So all in all, in line with plans, and hopefully that the two preclinical assets are going to generate an interesting news flow going forward as well. So now let's turn to some of the financials and we will start with the commercial performance. And as Kai alluded to, she did highlight some of the numbers here. If you just look at the reported numbers for the, for the Corona, It says 0.6% growth, but if we adjust for discontinued partnership, it's actually more than 9% for the quarter, 7% full year. But more interestingly, it is to look at the individual business legs where we saw Travel Health growing 32% when adjusted for third-party products. and 34% on a nine-month basis. So strong, strong growth from our travel business and solid execution on our public preparedness business. I've already addressed some of these. The rapist business, 38% growth. Insepur, 9% growth despite the challenges that we have been facing. Vimkunja, 258%. It's obviously a new launch. So all in all, very strong growth. We also saw VivoTiff growing strongly. Vaxcora, small product that is typically driven more by outbreaks and specific orders. So all in all, on a nine-month basis, nearly 4.8 billion Danish kroner. So let's turn to the full P&L. We already touched upon the top line. If we then turn to the gross profit, we delivered 52% for the corner. It's up a couple of percentage points compared to last year, driven by a good product and country mix. If you look into the quarter in itself, then there were things contributing positively, and that is definitely product and country mix. A lot more sales into the U.S. and a lot more rate of sales. But then on the more challenging front, we also We had some challenges when we changed from TBE campaign manufacturing first half of this year and during the summer, we were switching over to rapiers. That changeover took longer than anticipated, which meant that basically we couldn't manufacture for three to four weeks. And that, of course, also has an impact on the gross margin. But it's all, you can say, absorbed within the numbers that you see here. And still, we come out with quite a solid gross margin here. and we are right now up and running with rapiers according to the plans again. Total operating costs, somewhat below last year's level for the quarter and mainly explained by some of the initial VinCunha launch costs that were included in the third quarter of last year and then also some costs associated with the takeover attempt last year as well. If we take it all down to the bottom line, then we see we are delivering an extraordinary 34.4% EBITDA margin, very strong EBITDA margin, also above the, you can say, the stated ambition level of 25 to 30% that we have announced previously. When we compare to last year, we have to remember that in the Q3 of last year, we sold a priority review voucher, which gave us 810 million in income. If you deduct that from the EBITDA, then you are actually comparing to a 28% EBITDA last year. So we are up 6% this point in terms of profitability as well. On a nine-month basis, also close to 35% EBITDA and an EBITDA of 1.7 billion Danish kroner. So very, very strong performance on the P&L this year. Next slide deals with the cash flow. And of course, strong EBITDA typically means you're also delivering a strong cash flow. And if we look at the quarter in itself, it was 809 million cash flow from operating activities, cash flow from investment activities. These are mainly placement of cash into securities, so really not as such consuming the cash, giving us a free cash flow of more than 500 million Danish kroner. The cash flow from financing activities is $170 million. That's all explained, more or less, by the share buyback programs we have done during the quarter. And still, after the share buybacks, we are delivering net cash flow of $372 million. So very, very strong cash flow generation as well. If you look at the cash flow for the nine months, you have to remember that we During that period of time, we paid back the last milestone to GSK, €70 million, which is impacting the cash flow from operating activities. If you have obviously deducted from that, you will also see that it's a very strong performance for the full nine months. Final page, I will just use that one to remind you of our current outlook for the year. Thank you.
Conference Operator
Operator
To ask a question, you will need to press star 1 and 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 and 1 again. One moment for our first question. And this one comes from Thomas Bowers from SAB. Please go ahead.
Thomas Bowers
Analyst, SEB
Yes, thank you very much. A few questions from me here. So, maybe just to kick off with your 2016 guidance. So, can you maybe comment a little bit on the in-flight Q4 revenue outlook? So, travel health revenue, approximately, well, 500 million plus minus. So that implies a deep sign-off of 20% or maybe 10% if you adjust for the partner for a fail. So what actually explains this implied slowdown? Also given that maybe Intifor should maybe recover a little bit at least. And then on Vint Cunha, so sales very strong this quarter with I guess almost doubled here quarter to quarter. And I understand Germany is appearing to be the key driver here. Can you maybe just explain some of the differences between or across Europe on the uptake and then and maybe how we should think about the pace of that market development in Europe going forward. And then, just the last question, just on capacity, so exceptional Ravikur demand, obviously, but I'm a little bit curious on manufacturing capacity, so will that still be sufficient if you continue that strong growth going into 2027? Thank you Thomas for the questions here. So let me address the first one on the guidance.
Henrik Juuel
Chief Financial Officer
I think first of all, don't forget what our guidance says approximately, and we are guiding 3.4 billion on travel health. There can of course be variations to that. It is an approximate guidance. And then don't forget the seasonality as well. And if you look at the EBITDA margin and the Q4 there, I think the reason for that is that we are targeting a lower EBITDA margin for the Q4 in itself, is first of all, Thank you.
Tara Stenbaum
Chief Executive Officer
Maybe I'll say a few words on Limpunja. You asked specifically about the Europe. Then saying about the U.S., and Henrik highlighted that we have some access topics at the moment. Still, I think it's important that the disease, you know, in the U.S. as well, so we continue working hard as well in terms of raising awareness, making sure that the base profile of our vaccine is well known as well, knowing that there was a vaccine that was withdrawn from the market. And when it comes to Europe, obviously Germany as often is the kind of number one market in Europe, and we're very pleased how we see the takeoff in terms of travelers and the doctors adapting the vaccine, as well as working markets around. We also start seeing cases of chikungunya. I think the other week there was a case in South of France, for example. So I think the disease, even in Europe, it's in infancy at the moment. So, as usually in launch, we go a bit step by step and we're learning as we're moving forward, but we are very pleased in terms of how we see the progress in Europe at the moment.
Henrik Juuel
Chief Financial Officer
I don't know, Henrik, if you have... Maybe I can just add one thing, and that is when you look at the quarterly numbers on Vinconia, don't expect sort of a smooth curve because we are launching into many countries and therefore it can be a little lumpy when you sort of supply into the whole supply chain. So it will probably not be a smooth curve one day when we look back on how we entered this market here. But as we sit here right now, today, we are confident that we will meet the self-guidance we have provided of 200 million.
Tara Stenbaum
Chief Executive Officer
And of course, the U.S. trade is important while we are in the European Union.
Henrik Juuel
Chief Financial Officer
Yeah.
Tara Stenbaum
Chief Executive Officer
And then, is that that answer?
Henrik Juuel
Chief Financial Officer
Yes, then there was one on capacity.
Tara Stenbaum
Chief Executive Officer
Yeah. Then the capacity, I will also say that, you know, looking at the organization, we've been able to really deliver well on this growing demand. US, we've had no supply issues this year at all. And we've done sort of quick wins as well, smartly. I call it quick wins in manufacturing to really keep up with it. And obviously, being a life-saving vaccine, that's playing such an important role with the high market share in many countries. That's a real priority for us going forward. and making sure with the forecast for the future that we have the right manufacturing and supply capabilities that can work effectively and deliver. And we have to estimate and see with the demand then what type of investments we need to put into that case. And then the question about end support and maybe you want to elaborate on this one as well, Henrik.
Henrik Juuel
Chief Financial Officer
Yeah, I think you explained it pretty well, Tai. I think what we have done right now is that we've done everything we can in terms of easy wins. We did during the summer break here, we changed the bat sizes. We're going to do that again during the Christmas shutdown. And I think we are quite confident that that will enable us to supply into expected demand during 27. But of course, we are constantly looking at this. And as we talked about it before, we need to really to Thank you. We're now going to take the next question.
Conference Operator
Operator
and this one comes from Romy O'Connor from Kampen. Please go ahead. Hello.
Romy O'Connor
Analyst, Kempen
Thank you for taking our questions and thank you for the presentation. I also have one on Zimp Cunha. So with the U.S. uptake expectedly slower, I was just wondering if you can clarify a bit more on what the conservative approach you mentioned meant from the CDC. Regarding timelines for the MMWR publication, what could the 2027 ramp then look like if that wouldn't happen? And maybe more of a general question, so with the second transfer, the buyback underway, also the strong cash position, I'm just wondering what we should expect to learn about how you'll weigh investments in the existing portfolio, maybe potential M&A and further buybacks in the strategic presentation in the next half of 2027. Thank you. Thank you.
Henrik Juuel
Chief Financial Officer
Thank you.
Tara Stenbaum
Chief Executive Officer
Do you want to elaborate a bit on the U.S. side and then I can talk about the investments?
Henrik Juuel
Chief Financial Officer
Yeah. So thanks, Romi. What I mentioned regarding the conservative approach by the U.S. government on the recommendation is there is currently a recommendation in the U.S. that if you travel to a country with a current outbreak, you should get vaccinated. A conservatism comes in for how do you determine a current outbreak. And in the U.S., that is defined by a U.S. citizen coming back to the U.S. Will Tickengunya, which is very, very late in the process. And what it actually means that if you look up on the BBC's website today, there are only three countries listed, the current outbreaks. At the similar European side, I believe there are more than 15 countries listed because here they actually monitor ongoing real outbreaks. So it's a rather conservative definition of an outbreak in the US. And then of course, combined with the fact that they have not yet confirmed the ASIC recommendation in the MMWR application and that is normally more of an administrative task. It doesn't mean we can't sell, but it means that some of the customers are reluctant to buy because they are breaking sort of their normal routines. They normally look up in the MMWR to find the recommendations and if they can't, they say, okay, then we are not buying. So it's just providing a short-term headwind to us. We do believe that this is something that will over time be resolved. It will take time. of course to work with the government. We know that U.S. is one of the markets where you do now and then have outbreaks of chikungunya as well, and we think that will eventually also convince people of the need to have a vaccine available in the market and to have a good recommendation in place. So that was the question on vincunia. Then we have the question on buybacks. You're right, we are doing buybacks at the moment. Sorry, there's some noise in the background. I don't know how it comes in here. Okay, I'll continue. We are right now, as we have reported, we just finished the first trance of the 750 million buyback and we this morning announced the start of the next. We are in a very, very solid financial position. We have reported, despite the share buybacks, nearly 3 billion Danish kroner of cash. So we have plenty of cash at the moment. If you look in our R&D, you talked a little about investing in our current portfolio and inorganically as well. Part of our money really goes into what we call lifecycle management to make sure that we improve the position of all our products. And a lot of that is really some of the label expansion opportunities we have to make sure that our products are covering as broad as possible in the market. So that's one of the areas where we invest. And then we have the M&A part, which remains part of our strategy. We are constantly looking at opportunities, but we are also extremely picky. We only want something that is generating revenue. That's our current focus at least, that is generating revenue from day one. It's not diluting our profitability, and that fits in with our commercial infrastructure. So we have decided that right now we are striking a good balance between preserving
Tara Stenbaum
Chief Executive Officer
And maybe to build on Henrik's answer, at the moment we are working, in this moment is a good momentum to take a look at the opportunities that we have. I would say a lot around us, where do we stand by investing our current business and how can we make that grow and get the full potential out of it and then also look at Thank you. We are now going to take the next question. And this one is from Håkon Ham from Danske Bank. Please go ahead.
Håkon Ham
Analyst, Danske Bank
Great, thank you for taking my questions. An entire welcome and congratulations on the new role. A couple of questions from my side. On rabies at the Q2 call, you explained that the wholesaler inventory build-up had amplified growth and your Q3 sales are now up 37% both in quarter and quarter and year over year, as you mentioned. While your commentary now seems more focused on underlying demand, so can you elaborate on that? Was the Q3 performance purely driven by underlying demand, or did the wholesaler inventory movements also contribute? And now, and just to follow up on M&A, because you say that you are constantly looking at M&A, but with you, Taya, now in the role, and Henrik preparing to leave, Are you still actively pursuing M&A opportunities in this transition period, or has it become less of a priority until a full team is ready?
Henrik Juuel
Chief Financial Officer
Let me take the rapist one. I think what we said during the Q2, you're right, Håkon, thanks for the question, by the way. We did say that the wholesaler inventory probably amplified the growth. And I think what is happening when a market is growing as fast as we are seeing here with rapists, as we talked to earlier, in the beginning of the year we saw 20% growth, but it's actually been accelerating up to 50% growth. Then what is happening at the wholesaler level, they typically try to have a certain number of days on inventory, so they constantly also increase their holdings. and Paul John Chaplin. That is in-market data, there is a time lag to hours and we of course record what we sell to the wholesalers. But I think this amplification is simply an effect of such increased demand as wholesalers, they typically define their inventory levels as on the days of sales compared to expected future sales. So I think that was on the radius, then we had the M&A.
Tara Stenbaum
Chief Executive Officer
So I would say yes, M&A continues to be part of our strategy as it's been in the past year and I would say it's been the DNA of Bavaria and the whole travel business has been built on the M&A. When I then talk about us sharpening the strategy going forward and next year we gave our last guidance, 24 longer-term guidance. So I think it's a good momentum right now with sales that are exceeding expectations to a little bit Thank you. We're going to take the next question.
Conference Operator
Operator
and this one is from Peter Hugh Griffey from Nordea. Please go ahead.
Peter Hugreffe
Analyst, Nordea
Hi, Peter Hugh Griffey from Nordea. Thank you so much for taking my questions and again also welcome to you, Tara. Two questions. Firstly, I can see that you quoted in Danish media that you are talking about a strategic change, which of course is interesting. So can you maybe give us a little bit of comfort around this strategy review? What is the direction? What is it that you're looking for? And so on. That's the first question. Then secondly, your predecessor, one of the last things he did was to up the public preparedness outlook from 1.5 to 2 billion to actually 2 billion Danish. And now I can see that either it's forgotten or you have retracted on that part. So is it 2 billion as a base or are we back to 1.5? Thank you so much.
Tara Stenbaum
Chief Executive Officer
Well, thank you, Peter, and thanks for welcoming me to my new role. I go back to your question about this strategy. I think we're doing well, and as I said, it's a very strong and solid base to continue the business. When you grow with the speed and change that Bavarian Nordic has done, they created another business besides the DNA platform. You can see that there's many things ongoing, and people are committed. They take a lot of action. I think it's a good way to make sure we channel the energy exactly to the right place. That's what I'm calling sharpening the strategy. Make sure that we really focus on the right priorities under existing business as well as looking at the M&A opportunities so that we really scale the platform in terms of growing that platform that we can then absorb more growth either organically or inorganically. We have a very young commercial organization still. It has been there only a few years, but we're also making sure that in that time we focus on what matters the most in terms of understanding the markets, focusing on the markets that are the most critical going forward. I don't know if that gives you a clear view, Peter?
Peter Hugreffe
Analyst, Nordea
For me, it sounds more like you're focusing on how can you execute on your strategy rather than kind of a review of the current, but maybe it's semantics.
Tara Stenbaum
Chief Executive Officer
Yeah, maybe it is a semantics. I think you need to take a holistic view of each sector of our business, where is the public fairness, there is the business of travel help, and then you look at the M&A side. So you look at holistically the three pillars and you might be clear on the direction going forward.
Henrik Juuel
Chief Financial Officer
Got it. Great, and thanks Peter for the questions here. To the other one on public preparedness, we have not officially changed our guidance on that one, so our medium term guidance. It remains 1.5 to 2 billion. I think what Paul said is that looking at what we have achieved so far, I think he said we are probably closer to the 2 billion, but we have not officially changed that one. I think this year is a good example. We are delivering 2.5 billion. That could argue, of course, for going above the one and a half to two, but it's also still very sensitive to few big orders. So next year, as Taja alluded to, we will come out with a sharpening strategy and at the end of next year, our mid-term financial targets are also sort of expiring, which we announced at the Capital Markets Day in 24. So in connection with that, it would be natural to sort of also restate what is the base business level for public preparedness. So far, it stays at the 1.5 to 2 billion, but we're very happy that even this year, in a year where there is no material impact, we are delivering 2.5, so significantly above that base business level.
Peter Hugreffe
Analyst, Nordea
Got it. Can I have a follow-up on the public preparedness? Sure. So, it's just when I compare with the We actually did compare with last year, then you have secured 900 and last year it was 1.1. So, I mean, is it fair to assume that you are almost kind of at the same level for 27 based on what you see right now? Or is there any kind of lumpiness in what you have secured already now compared to last year? Just trying to understand kind of . Does that make sense?
Henrik Juuel
Chief Financial Officer
No, I think it's fair. I think if you asked us two months ago, we probably said we are ahead of last year. But if you look at it right now, we are probably more or less same place as we were this time last year with 900 million, I wouldn't say in the bank, but at least all are secured. So we feel that we are in a good position also to deliver within the ambition level for next year.
Benjamin Jackson
Analyst, Jefferies
Okay. Good. Good. Thank you. Thank you.
Conference Operator
Operator
Thank you. We are now going to take the next question. And this one is from Benjamin Jackson from Jefferies. Please go ahead.
Benjamin Jackson
Analyst, Jefferies
Thank you for the question. Just one for me this time. I'm interested to know whether you have any colleagues and provide on how European rabies market would react to a new entrant in that market. Obviously, one of your competitors is hoping for approval towards the end of this year. How do we think about the spillover of that on either price or volumes to you guys? And is there anything else worth flagging about contracting timelines, etc. So any thoughts around that would be super useful. Thank you.
Tara Stenbaum
Chief Executive Officer
Well, thank you. Thank you, Benjamin, for the question. What I've seen so far, I think our rabies position in kind of key market is really strong if I look at the US and Germany. We've been a good partner in terms of supply, constantly, and the vaccine has been market for a long time with the very, very strong data. So in terms of the competitor and what they can offer, I think We're in a very good position to keep the leadership and the strong position in the market going forward. And at the moment as well, it is a growing market. So our job as well is to make sure that we, you know, increase the awareness and make sure that people would get vaccinated that they should going forward. Does that answer your question, Benjamin?
Benjamin Jackson
Analyst, Jefferies
Yes, I guess to some extent, thank you.
Conference Operator
Operator
Thank you. There are no further questions for today. I will now hand the call back to Tarja Sandvold for closing remarks.
Tara Stenbaum
Chief Executive Officer
Well, thank you everyone for attending the call and for your questions and for welcoming me as well. With this, I hope you as well have a very nice weekend.
Conference Operator
Operator
Thank you. Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.